Clinical Trial Update: Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of durvalumab and tremelimumab in chemotherapy-naive metastatic castration-resistant prostate cancer has completed; results were posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 2 | Status: COMPLETED | Results posted: 2022-05-25